期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 14, 期 1, 页码 5-8出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.2016.1100535
关键词
CCR5 antagonist; maraviroc; off-label use
Maraviroc is a first-in-class selective CCR5 antagonist only approved in combination with other antiretrovirals for the treatment of HIV-infection. However, sometimes, off-label prescribing is necessary. In this regard, interesting data have been obtained with maraviroc from studies using murine models. In human daily clinical practice there are many researching areas of interest where CCR5 could play an important role. Nowadays few clinical trials are evaluating maraviroc's role in non-HIV-infected patients but there are many open issues that need to be answered about CCR5 antagonists. In this article we review some of them.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据